Related Experiment Videos
Survival of children with chronic myeloid leukemia
T Marin1, A Butturini, H Kantarjian
1Department of Pediatric Hematology, Centro Medico La Raza IMSS, Mexico City, Mexico.
Insights
Survival for children with Philadelphia-chromosome-positive chronic myeloid leukemia (CML) is poor with conventional therapies. Bone marrow transplantation should be considered for improved outcomes in pediatric CML patients.
Area of Science:
- Pediatric Hematology
- Oncology
- Leukemia Research
Background:
- Philadelphia-chromosome-positive chronic myeloid leukemia (CML) is a rare but aggressive hematologic malignancy in children.
- Conventional therapies offer limited long-term disease-free survival for pediatric CML patients.
Purpose of the Study:
- To analyze survival data in children diagnosed with Philadelphia-chromosome-positive CML.
- To evaluate the efficacy of current treatments and inform future therapeutic strategies.
Main Methods:
- Retrospective analysis of survival outcomes in a cohort of 203 children with Philadelphia-chromosome-positive CML.
- Statistical evaluation of median survival and average annual risk of death.
Main Results:
- The median survival for pediatric CML patients in this cohort was 4.1 years.
- The average annual risk of death was 20%, indicating a high mortality rate.
- Survival data were comparable to those reported for adult CML patients.
Conclusions:
- Conventional therapies are insufficient for achieving long-term disease-free survival in children with CML.
- Bone marrow transplantation should be strongly considered as a potentially curative treatment option for pediatric CML.
Abstract:
We analyzed survival in 203 children with Philadelphia-chromosome-positive chronic myeloid leukemia (CML). Median survival was 4.1 years; average annual risk of death was 20%. These survival data are similar to those reported in adults. Because there is no possibility of long-term disease-free survival in children with CML with conventional therapies, the findings of this study suggest that bone marrow transplantation should be considered in these patients.